[
    [
        {
            "time": "2023-10-18",
            "original_text": "贝达药业ALK抑制剂恩沙替尼新适应症上市申请获受理",
            "features": {
                "keywords": [
                    "贝达药业",
                    "恩沙替尼",
                    "ALK抑制剂",
                    "新适应症",
                    "上市申请",
                    "受理"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业ALK抑制剂恩沙替尼新适应症上市申请获受理",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "贝达药业(300558.SZ)：盐酸恩沙替尼一线治疗适应症药品注册申请获受理",
            "features": {
                "keywords": [
                    "贝达药业",
                    "盐酸恩沙替尼",
                    "一线治疗",
                    "适应症",
                    "药品注册",
                    "受理"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：盐酸恩沙替尼一线治疗适应症药品注册申请获受理",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "2021年医药生物中期策略报告：需求长期景气 布局创新、医疗服务和消费主线",
            "features": {
                "keywords": [
                    "医药生物",
                    "中期策略",
                    "需求",
                    "景气",
                    "创新",
                    "医疗服务",
                    "消费"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "医疗服务",
                    "消费"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2021年医药生物中期策略报告：需求长期景气 布局创新、医疗服务和消费主线",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        }
    ]
]